<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887340</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A01615-38</org_study_id>
    <secondary_id>2012/1884</secondary_id>
    <nct_id>NCT01887340</nct_id>
  </id_info>
  <brief_title>Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma</brief_title>
  <acronym>SEMITEP</acronym>
  <official_title>Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic
      strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I
      (cohort 1) or metastatic (cohort 2) seminoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients without pathological fixation</measure>
    <time_frame>Assessed at the time of inclusion or after 2 cycles of chemotherapy, up to 21 days</time_frame>
    <description>Rate of patients without pathological fixation at the time of the inclusion PET-TDM (cohort 1) or at the time of the PET-TDM following two cycles of chemotherapy (Etoposiede+Cisplatine) (cohort 2) and getting a lighten protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients without pathological fixation</measure>
    <time_frame>Assessed at the time of inclusion or after 2 cycles of chemotherapy, up to 21 days</time_frame>
    <description>Rate of patients without pathological fixation at the time of the inclusion PET-TDM (cohort 1) or at the time of the PET-TDM following two cycles of chemotherapy (Etoposiede+Cisplatine) (cohort 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">271</enrollment>
  <condition>Seminoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET-TDM
carboplatine: Dose (mg) = AUC x (GFR + 25)
GFR : glomérulaire filtration (ml/min)
AUC : area under curve (mg/ml x min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET-TDM
ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)
carboplatine: Dose (mg) = AUC x (GFR + 25)
GFR : glomérulaire filtration (ml/min)
AUC : area under curve (mg/ml x min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>- carboplatine: Dose (mg) = AUC x (GFR + 25)
GFR : glomérulaire filtration (ml/min)
AUC : area under curve (mg/ml x min)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg/m2 D1 to D5</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>20 mg/m2 de D1 to D5</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria shared:

          -  Histologically proved seminoma after orchiectomy

          -  Primary testicular or retroperitoneal

          -  Normal alpha-fetoprotein before and after orchiectomy

          -  No prior treatment with radiotherapy or chemotherapy

          -  Age &gt;= 18 years

          -  ECOG 0 to 2

          -  PNN &gt;= 1500, platelets &gt;= 100 000, bilirubin &lt;= the upper limit nromale

          -  ASAT (SGOT) and ALAT (SGPT) &lt;= 1,5 x the upper limit nromale

          -  Serum creatinine &lt;140 µmol / L (or clearance&gt; 60 mL / min)

          -  Information and signed informed consent before inclusion in the study

          -  Patient affiliated to a social security

        Specific inclusion criteria for cohort 1:

          -  grade I

        Specific inclusion criteria for cohort 2:

          -  grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of
             the LDH)

          -  grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the
             LDH)

          -  grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and
             LDH &lt; 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis
             and LDH &lt; 2 times normal limit) either at initial diagnosis or relapse of a grade I
             seminoma)

          -  PET-TDM positive (pathological fixation on metastatic lesions)

        Exclusion Criteria shared:

          -  Patient infected by HIV, Hepatitis B or C

          -  History, within 5 years, of cancer other than seminoma, except for treated skin cancer
             (Basal Cell) .

          -  visceral metastasis

          -  cerebral metastasis

          -  Any physical or mental condition incompatible with the treatment (to the investigator
             discretion)

          -  Uncontrolled or severe cardiovascular pathology

          -  Uncontrolled or severe hepatic pathology

          -  Persons deprived of liberty or under guardianship

          -  Unable to undergo medical monitoring due to geographical, social or psychological
             reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yohann LORIOT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yohann LORIOT, MD</last_name>
    <phone>0142115276</phone>
    <phone_ext>+33</phone_ext>
    <email>yohann.loriot@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie LANOY</last_name>
    <phone>0142114121</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.lannoy@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohann LORIOT, MD</last_name>
      <phone>0142115276</phone>
      <phone_ext>+33</phone_ext>
      <email>yohann.loriot@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

